Media stories about Arsanis (NASDAQ:ASNS) have trended somewhat positive recently, according to Accern. Accern rates the sentiment of news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Arsanis earned a media sentiment score of 0.06 on Accern’s scale. Accern also gave press coverage about the company an impact score of 45.7796441463147 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
These are some of the media headlines that may have impacted Accern Sentiment’s scoring:
- Arsanis (ASNS) Lowered to “Hold” at Zacks Investment Research (americanbankingnews.com)
- Arsanis Out-Licenses Preclinical Stage E. coli Monoclonal Antibodies (finance.yahoo.com)
- Arsanis (ASNS) and The Competition Financial Review (americanbankingnews.com)
- Arsanis (ASNS) Upgraded to “Buy” at Zacks Investment Research (americanbankingnews.com)
- Analyzing Arsanis (ASNS) & Its Competitors (americanbankingnews.com)
ASNS stock traded down $1.52 during midday trading on Thursday, hitting $23.82. 17,690 shares of the stock were exchanged, compared to its average volume of 35,535. The stock has a market cap of $335.49 and a PE ratio of -1.47. Arsanis has a fifty-two week low of $10.40 and a fifty-two week high of $28.69. The company has a debt-to-equity ratio of 0.17, a quick ratio of 7.45 and a current ratio of 7.45.
ASNS has been the subject of several recent analyst reports. Piper Jaffray initiated coverage on Arsanis in a report on Monday, December 11th. They issued an “overweight” rating and a $23.00 price target for the company. Cowen initiated coverage on Arsanis in a report on Monday, December 11th. They issued an “outperform” rating for the company. Citigroup initiated coverage on Arsanis in a report on Monday, December 11th. They issued a “buy” rating and a $27.00 price target for the company. ValuEngine raised Arsanis from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd. Finally, Cantor Fitzgerald initiated coverage on Arsanis in a report on Wednesday, February 14th. They issued an “overweight” rating and a $26.00 price target for the company. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. Arsanis presently has an average rating of “Buy” and a consensus price target of $25.75.
Arsanis, Inc, a clinical-stage biopharmaceutical company, focuses on applying monoclonal antibody (mAb) immunotherapies to address serious infectious diseases. Its lead product candidate is ASN100, a first-in-class mAb therapeutic in Phase II clinical development for the prevention of staphylococcus aureus pneumonia.
Receive News & Ratings for Arsanis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arsanis and related companies with MarketBeat.com's FREE daily email newsletter.